Genetic risk scores enhance the diagnostic value of plasma biomarkers of brain amyloidosis
Vijay K. Ramanan(Mayo Clinic in Arizona), Prashanthi Vemuri(Mayo Clinic in Arizona), Jonathan Graff‐Radford(Mayo Clinic), Ekaterina I. Hofrenning(Mayo Clinic in Florida), Alicia Algeciras‐Schimnich(Mayo Clinic), Ronald C. Petersen(Mayo Clinic in Arizona), Robel K Gebre(Mayo Clinic), David S. Knopman(Mayo Clinic), Owen A. Ross(Jacksonville College), Daniel J. Figdore(Mayo Clinic), Val J. Lowe(Mayo Clinic), Michelle M. Mielke(Wake Forest University), Clifford R. Jack(Mayo Clinic)
Cited by 24
Related Papers
The diagnosis of dementia due to Alzheimer's disease: Recommendations from the National Institute on Aging‐Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease
|Alzheimer s & Dementia|2011|18.9k
NIA‐AA Research Framework: Toward a biological definition of Alzheimer's disease
|Alzheimer s & Dementia|2018|10.4k
Mild cognitive impairment as a diagnostic entity
|Journal of Internal Medicine|2004|7.8k
Toward defining the preclinical stages of Alzheimer's disease: Recommendations from the National Institute on Aging‐Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease
|Alzheimer s & Dementia|2011|7.1k
Mild cognitive impairment – beyond controversies, towards a consensus: report of the International Working Group on Mild Cognitive Impairment
|Journal of Internal Medicine|2004|5k